Anais da Academia Brasileira de Ciências
Print version ISSN 0001-3765
An. Acad. Bras. Ciênc. vol.85 no.1 Rio de Janeiro Mar. 2013 Epub Mar 05, 2013
http://dx.doi.org/10.1590/S0001-37652013005000018
BIOLOGICAL SCIENCES
ADRIANA L. DA SILVA1, RAQUEL S. SANTOS1, DÉBORA G. XISTO12, SILVIA DEL V. ALONSO3, MARCELO M. MORALES2, PATRICIA R.M. ROCCO1
1Laboratório de Investigação Pulmonar, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde,Av. Carlos Chagas Filho, s/n, Ilha do Fundão, 21941-902, Rio de Janeiro, RJ, Brasil
2Laboratório de Fisiologia Celular e Molecular, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Ilha do Fundão, 21941-902, Rio de Janeiro, RJ, Brasil
3Laboratorio de Biomembranas, Departamento de Ciencia y Tecnologia, Universidad Nacional de Quilmes, Roque Saenz Pena 352, Bernal, B1876BXD, Buenos Aires, Argentina
Nanotechnology is an emerging science with the potential to create new materials and strategies involving manipulation of matter at the nanometer scale (- 100 nm). With size-dependent properties, nanoparticles have introduced a new paradigm in pharmacotherapy – the possibility of cell-targeted drug delivery with minimal systemic side effects and toxicity. The present review provides a summary of published findings, especially regarding to nanoparticle formulations for lung diseases. The available data have shown some benefits with nanoparticle-based therapy in the development of the disease and lung remodeling in respiratory diseases. However, there is a wide gap between the concepts of nanomedicine and the published experimental data and clinical reality. In addition, studies are still required to determine the potential of nanotherapy and the systemic toxicity of nanomaterials for future human use.
Keywords: asthma; turberculosis; nanotechnology; lung cancer
pdf in English
No comments:
Post a Comment